KR20070058690A - 인다졸 화합물의 제조방법 - Google Patents

인다졸 화합물의 제조방법 Download PDF

Info

Publication number
KR20070058690A
KR20070058690A KR1020077009848A KR20077009848A KR20070058690A KR 20070058690 A KR20070058690 A KR 20070058690A KR 1020077009848 A KR1020077009848 A KR 1020077009848A KR 20077009848 A KR20077009848 A KR 20077009848A KR 20070058690 A KR20070058690 A KR 20070058690A
Authority
KR
South Korea
Prior art keywords
formula
compound
reaction
mixture
catalyst
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077009848A
Other languages
English (en)
Korean (ko)
Inventor
브리짓 레이 에와니키
에릭 존 플라히브
애니 쥬디스 카스파리안
마크 브라이언 미첼
마이클 데이비드 페리
스테이시 앤 오닐-슬라베키
닐 윌라임 사흐
제임스 에드워드 사엔즈
빙 샤이
네보자 슬로보단 스탠코빅
제이야람 카츠리 스리랑암
킹핑 티안
슈 유
Original Assignee
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 인코포레이티드 filed Critical 화이자 인코포레이티드
Publication of KR20070058690A publication Critical patent/KR20070058690A/ko
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
KR1020077009848A 2004-11-02 2005-10-21 인다졸 화합물의 제조방법 Ceased KR20070058690A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62463504P 2004-11-02 2004-11-02
US60/624,635 2004-11-02
US71707105P 2005-09-14 2005-09-14
US60/717,071 2005-09-14

Publications (1)

Publication Number Publication Date
KR20070058690A true KR20070058690A (ko) 2007-06-08

Family

ID=35744929

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077009848A Ceased KR20070058690A (ko) 2004-11-02 2005-10-21 인다졸 화합물의 제조방법

Country Status (14)

Country Link
US (1) US7232910B2 (https=)
EP (1) EP1809621A1 (https=)
JP (1) JP2008518900A (https=)
KR (1) KR20070058690A (https=)
AR (1) AR051754A1 (https=)
AU (1) AU2005300310A1 (https=)
BR (1) BRPI0518203A2 (https=)
CA (1) CA2586174A1 (https=)
IL (1) IL182693A0 (https=)
MX (1) MX2007005291A (https=)
NO (1) NO20071619L (https=)
RU (1) RU2007116107A (https=)
TW (1) TWI294421B (https=)
WO (1) WO2006048744A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ580126A (en) 2007-04-05 2012-03-30 Pfizer Prod Inc Crystalline forms of 6- [2- (methylcarbamoyl) phenylsulfanyl] -3-e- [2- (pyridin-2-yl) ethenyl] indazole suitable for the treatment of abnormal cell growth in mammals
JP5348725B2 (ja) * 2007-10-25 2013-11-20 ジェネンテック, インコーポレイテッド チエノピリミジン化合物の製造方法
EP2163544A1 (en) * 2008-09-16 2010-03-17 Pfizer, Inc. Methods of preparing indazole compounds
WO2010078897A1 (en) * 2009-01-08 2010-07-15 Merck Patent Gmbh Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
CN103826618A (zh) 2011-09-30 2014-05-28 辉瑞大药厂 N-甲基-2-[3-((e)-2-吡啶-2-基-乙烯基)-1h-吲唑-6-基硫烷基]苯甲酰胺的药物组合物
US9205078B2 (en) 2011-11-11 2015-12-08 Pfizer Inc. N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia
US9899120B2 (en) 2012-11-02 2018-02-20 Nanotek Instruments, Inc. Graphene oxide-coated graphitic foil and processes for producing same
US10087073B2 (en) 2013-02-14 2018-10-02 Nanotek Instruments, Inc. Nano graphene platelet-reinforced composite heat sinks and process for producing same
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
PT3077397T (pt) * 2013-12-06 2020-01-22 Vertex Pharma Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo
PL3102605T3 (pl) 2014-02-04 2019-06-28 Pfizer Inc. Połączenie antagonisty pd-1 i inhibitora vegfr do leczenia nowotworu
US9617222B1 (en) 2014-03-31 2017-04-11 Senju Pharmaceutical Co., Ltd. Alkynyl indazole derivative and use thereof
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
WO2016108106A1 (en) * 2014-12-29 2016-07-07 Shilpa Medicare Limited An improved process for preparation of axitinib
RU2714233C2 (ru) 2015-02-26 2020-02-13 Мерк Патент Гмбх Ингибиторы pd-1 / pd-l1 для лечения рака
US9580406B2 (en) 2015-04-28 2017-02-28 Signa S.A. De C.V. Processes for the preparation of axitinib
MY193229A (en) 2015-06-16 2022-09-26 Merck Patent GmbH Pd-l1 antagonist combination treatments
KR20190062515A (ko) 2016-10-06 2019-06-05 화이자 인코포레이티드 암의 치료를 위한 아벨루맙의 투약 용법
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
WO2020212253A1 (en) 2019-04-18 2020-10-22 Synthon B.V. Process for preparing axitinib, process for purifying the intermediate 2-((3-iodo-1h-indazol-6-yl)thio)-n-methylbenzamide, process for purifying axitinib via the axitinib hcl salt, solid form of the axitinib hcl salt
US20240117030A1 (en) 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof
WO2025157389A1 (en) 2024-01-22 2025-07-31 Iomx Therapeutics Ag Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7521447B2 (en) * 2003-03-03 2009-04-21 Array Biopharma Inc. P38 inhibitors and methods of use thereof
AU2004226586B2 (en) 2003-04-03 2008-12-11 Pfizer Inc. Dosage forms comprising AG013736
WO2006123223A1 (en) 2005-05-19 2006-11-23 Pfizer Inc. Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor

Also Published As

Publication number Publication date
RU2007116107A (ru) 2008-11-10
AU2005300310A1 (en) 2006-05-11
WO2006048744A1 (en) 2006-05-11
AR051754A1 (es) 2007-02-07
US7232910B2 (en) 2007-06-19
JP2008518900A (ja) 2008-06-05
NO20071619L (no) 2007-04-25
EP1809621A1 (en) 2007-07-25
US20060094881A1 (en) 2006-05-04
CA2586174A1 (en) 2006-05-11
IL182693A0 (en) 2007-09-20
MX2007005291A (es) 2007-07-19
TW200621721A (en) 2006-07-01
BRPI0518203A2 (pt) 2009-03-10
TWI294421B (en) 2008-03-11

Similar Documents

Publication Publication Date Title
KR20070058690A (ko) 인다졸 화합물의 제조방법
US20070203196A1 (en) Methods of preparing indazole compounds
JP2008518901A (ja) インダゾール化合物を調製するための方法
CN101094836A (zh) 制备吲唑化合物的方法
CN111961034A (zh) 用作ret激酶抑制剂的化合物及其应用
CN107709298A (zh) 作为溴结构域抑制剂的螺[环丁烷‑1,3’‑二氢吲哚]‑2’‑酮衍生物
CN111183130A (zh) 苯并杂环衍生物及包含其的医药组合物
CN112585126B (zh) 四环化合物的制备方法
CN102140081A (zh) 制备抑制香草素亚型1(vr1)受体的吲唑基脲的方法
JP4820295B2 (ja) イソインドール誘導体の製造方法
TWI468405B (zh) 1H-吡唑并〔4,3-c〕異喹啉衍生物、其製備及其於醫療上之應用
WO2017167251A1 (zh) 1-(芳基甲基)喹唑啉-2,4(1h,3h)-二酮的制备工艺
TWI884151B (zh) 製備4-苯基-5-烷氧基羰基-2-噻唑-2-基-1,4-二氫嘧啶-6-基]甲基]-3-側氧-5,6,8,8a-四氫-1H-咪唑并[1,5-a]吡-2-基]-羧酸之替代方法
JP5315337B2 (ja) トポテカン塩酸塩の結晶形およびその製造方法
BRPI0708560A2 (pt) processo para a preparação de um composto, e, composto
KR20060085631A (ko) 아자바이사이클로[3.1.0]헥산 화합물의 제조방법
EP2163544A1 (en) Methods of preparing indazole compounds
JP2003531837A (ja) ナフトアミジン系ウロキナーゼ阻害薬
CN114621155A (zh) 一种制备卡马替尼的方法
KR101865868B1 (ko) 1-이소프로필-3-[5-[1-(3-메톡시프로필) 피페리딘-4-일]-[1,3,4]옥사디아졸-2-일]-1h-인다졸 옥살레이트의 대규모 제조공정
KR100758522B1 (ko) 신규 벤즈아미드 유도체 및 이의 제조법
JPH0316352B2 (https=)
HK40103024A (zh) 制备氨基嘧啶衍生物的改善方法
JP2025518047A (ja) TRPM3媒介性障害を治療するためのピラゾロ[1,5-a]ピリジン誘導体
WO2022257833A1 (zh) 取代的苯基丙烯基吡啶类衍生物中间体及其制备方法

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20070430

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20081024

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20090106

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20081024

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I